Multikine (Leukocyte Interleukin, Injection)
Advanced Primary Head and Neck Cancer
Phase 3Completed; Preparing BLA/NDA submission
Key Facts
Indication
Advanced Primary Head and Neck Cancer
Phase
Phase 3
Status
Completed; Preparing BLA/NDA submission
Company
About CEL-SCI
CEL-SCI is a publicly traded biotech company (NYSE American: CVM) founded in 1983, dedicated to developing immune-based therapies for cancer, autoimmune, and infectious diseases. Its core strategy involves activating the immune system at the point of diagnosis, before the immune system is compromised by conventional treatments. The company's landmark global Phase 3 trial in head and neck cancer, one of the largest ever in the indication, demonstrated a 14.1% absolute overall survival advantage at five years, positioning Multikine for a potential regulatory filing and a new treatment paradigm in oncology.
View full company profile